title: Oligo safety working group exaggerated pharmacology subcommittee consensus document.
abstract: This document summarizes the current consensus opinion of the Exaggerated Pharmacology (EP) Subcommittee of the Oligonucleotide Safety Working Group on the appropriate strategies to assess potential adverse effects caused by an "exaggerated" degree of the intended pharmacologic activity of an oligonucleotide (ON). The Subcommittee focused its discussions primarily on the ON subclasses that impact expression of "host" (i.e., human gene products--antisense, small interfering RNAs, and related ONs that target messenger RNA), with later and more limited discussions on aptamer, immunostimulatory, and microRNA subclasses. It is expected that many of these principles will be relevant to other subclasses but will need to be carefully considered as those development programs advance towards clinical trials. The recommendations may also serve as a frame of reference when designing Good Laboratory Practice safety studies with ONs, with regard to the study design elements that address assessment of EP. It is also hoped that these recommendations will establish a foundation for discussion with regulatory agencies on this subject.
authors.affiliation: Preclinsight, Reno, Nevada 89502, USA. preclinsight@yahoo.com
authors.forename: Doug
authors.initials: D
authors.lastname: Kornbrust
authors.forename: Joy
authors.initials: J
authors.lastname: Cavagnaro
authors.forename: Arthur
authors.initials: A
authors.lastname: Levin
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Foy
authors.forename: Pamela
authors.initials: P
authors.lastname: Pavco
authors.forename: Christina
authors.initials: C
authors.lastname: Gamba-Vitalo
authors.forename: Alain
authors.initials: A
authors.lastname: Guimond
mesh_terms: D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000627:therapeutic use; D026683:Advisory Committees; D000818:Animals; D052157:Aptamers, Nucleotide / Q000009:adverse effects / Q000627:therapeutic use; D015870:Gene Expression; D006801:Humans; D035683:MicroRNAs / Q000009:adverse effects / Q000627:therapeutic use; D009841:Oligonucleotides / Q000009:adverse effects* / Q000145:classification / Q000627:therapeutic use; D010601:Pharmacology, Clinical; D034622:RNA Interference; D012449:Safety; D013045:Species Specificity
chemical_list: D000276:Adjuvants, Immunologic; D052157:Aptamers, Nucleotide; D035683:MicroRNAs; D009841:Oligonucleotides